The first two authors contributed equally to this work 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-lH-l,2,4-triazole (ST1959) has shown therapeutic effects in several animal models ofautoimmune diseases. In this study the effects ofST1959 were further investigated in a murine model of colitis. The evidence obtained indicates that the beneficial effects exerted by ST1959 rely upon a decreased local immunological response. The cellular effects of ST1959 were additionally investigated on human peripheral blood mononuclear cells and Jurkat T cells by measuring cytokine production, cell proliferation and activation of a set of transcription factors. ST1959 decreases human T cell proliferation and inhibits cytokine expression at the transcriptional level. Moreover, at doses inhibiting cytokine production, ST1959 blocks phorbol 12-myristate 13-acetate (PMA) and ionomycininduced nuclear factor protein of activated T cell (NFATl) activity, without impairing AP-l-and NF-KBdependent transcription. Immunofluorescence data show that ST1959 inhibits the nuclear residency of NFATI in both Jurkat and human peripheral blood mononuclear cells activated with PMA/ionomycin. leptomycin B, an inhibitor of CRMlIexportinla-dependent nuclear export, reverted the inhibitory effect of ST1959 on NFATI nuclear localization. This indicates that ST1959 may increase the nuclear export of NFATl, down regulating NFATI activity via a mechanism different from that of cyclosporin A, since it does not affect NFAT phosporylation/dephosphorylation steps. These findings provide new insights into the molecular mechanisms underlying the immunomodulatory activity of ST1959. ST1959 (formerly known as DUll-IT), i.e. 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1 H-I ,2,4 triazole, was first described as a non-hormonal postimplantation anti-fertility agent (1). It exhibited many immunomodulatory properties in vivo, e.g., inhibition of antibody responses (both T cell-dependent and independent) and prolonged skin graft survival in mice (2). Moreover, ST1959 improved the clinical score in two animal models of systemic lupus erythematosus and collagen-induced arthritis (3), and it was effective in reducing macroscopic and histological colonic damage in an experimental model of colitis in the rat (4). Efficacy in controlling renal transplant rejection and Graft versus Host Disease was also reported
. Decreased thymus cellularity and altered thymocyte composition in STl959-treated mice differs from those observed in cyclosporin A-and leflunomide-treated animals, suggesting that STl959 acts through a mechanism different from that of these immunosuppressive drugs (3) .
Activation of T lymphocytes leads to a rapid increase in the expression of genes important for growth, differentiation, and cell adhesion. Transcription factors, such as nuclear factor protein of activated T cells (NFAT), nuclear factor-kappa B (NF-KB) and activating protein-l (AP-l), play key roles in this process. Activation-induced dephosphorylation ofNFAT proteins by calcineurin, a calcium/calmodulin-dependent serine-threonine phosphatase, results in nuclear import of NFAT (7) . After nuclear translocation, NFAT binds to its consensus DNA sequence, facilitating the start of NFAT-dependent gene transcription (8) . The two immunosuppressive drugs, cyclosporin A and FK506, both inhibit calcineurin activity, thereby preventing NFAT nuclear entry and NFAT-dependent gene transcription (9) . Today, these drugs are widely used clinically, although with severe side effects in certain cases (10) . The aim of this study is to shed light on the mechanism(s) behind the beneficial effects of STl959.
MATERIALS AND METHODS

Chemicals and Reagents
Reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. ST1959, i.e. 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1 H-l ,2,4 triazole, was synthesized by Edmond Pharma (Edmond Pharma Srl, Paderno Dugnano, Italy).
Cell culture
The human T leukemic cell line Jurkat (TIB-152, American Type Culture Collection, Manassas, VA) was maintained in suspension culture in RPMI 1640 medium containing 25 mM HEPES and 2 mM L-glutamine (Gibco, Grand Island, NY) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Gibco, Grand Island, NY) and 50 ug/ml, gentamycin. The cultures were kept at 37°C in a humidified 95% air, 5% CO 2 atmosphere.
Trinitrobenzene sulfonate induction ofcolitis
Colitis was induced in specific pathogen-free five to six-week-old female SJL mice (Charles River, Calco, Italy), n=50. Mice were housed under a light-dark cycle, keeping temperature and humidity constant. Parameters of the animal rooms were as follows: 22±2°C temperature, 55±1O% relative humidity, about 15-20 filtered air changes/hour and 12 hour circadian cycle of artificial light (7 a.m., 7 p.m.). Drinking water was supplied ad libitum. Animals were offered a daily complete pellet diet (GLP 4RF21, Mucedola) throughout the study. The care and husbandry of animals were in compliance with the European Community guideline 86/609 and Italian legislation. To induce colitis, 2.5 mg of the haptenating agent, trinitrobenzene sulfonate in 45% ethanol (vol/vol), were slowly instilled in the rectum (150 ilL/mouse) by inserting a rubber cannula fitted onto a l-mL syringe into the lumen of the colon 2.5 em proximal to the anal verge (11). After trinitrobenzene sulfonate instillation, animals were kept in a vertical position for 30 s, then the total volume was expelled with additional air before removing the cannula and returning the animals to their cages. ST1959 (0.5 mg/kg) in sesame oil was administered subcutaneously I h after TNBS administration and again on days 2 and 4. Animals were sacrificed on day 5. Colonic specimens were removed and assessed macroscopically. The percentage damaged colon area was calculated using a densitometric analysis software-Kodak ID Image Analysis software (Eastman Kodak cmp, New Haven CT). The experiment was repeated three times.
Enrichment oflamina propria mononuclear cells
Lamina propria mononuclear cells were prepared, as described by Boirivant (11) . Briefly, the colonic specimens were washed in calcium-and magnesium-free Hank's balanced salt solution (Gibco, Grand Island, NY), then cut into 0.5 em pieces and incubated twice in said salt solution containing 0.75 mM ethylenediamine tetraacetic acid and I mM dithiothreitol at 37°C for 15 min. Next, the tissue was digested in RPMI containing collagenase D (400 U/mL) and DNase I (0.01 mg/mL) (Roche Applied Science, Indianapolis, IN). The cells released from the tissue were then layered on a 40-100% Percoll gradient (GE-Healthcare, Buckinghamshire, UK), and lamina propria mononuclear cell-enriched populations were isolated from the cells at the 40-100% Percoll interface.
Stimulation and measurement of cytokine production by lamina propria mononuclear cells
To measure the capacity of isolated lamina propria mononuclear cells to produce cytokines, the cells (I x10 6 cells/mL) were incubated in 48-well plates pre-coated with differentiation antigen 3 (CD3) monoclonal antibody (10 ug/ml, overnight in 100 mM carbonate buffer, pH 9) and soluble anti-CD28 (I ug/ml.) in complete medium containing 10% FCS. Supernatants were harvested after 48 h, and assayed for the presence of Interleukin (IL)-2, Interferon (IFN)-y and IL-IO by specific Enzyme-Linked Immunosorbent Assay (ELISA) kits following the manufacturer's instructions (R&D Systems, Minneapolis, MN). Absorbance was read using a Sirio S Seac Microplate Reader (Radim S.p.A., Pomezia, Italy).
Human peripheral blood mononuclear cells and Jurkat cell stimulation
Peripheral blood mononuclear cells from healthy adult donors were isolated by density gradient centrifugation using Ficoll-Paque (GE-Healthcare, Buckinghamshire, UK). For proliferation experiments, peripheral blood mononuclear cells were stimulated in vitro for 48 h in the presence of plate-immobilized anti-CD3 (coated overnight using 10 /lgl mL in PBS) and soluble anti-CD28 (1 ug/ml.) monoclonal antibodies (BD Biosciences, Milan, Italy) in the presence or absence of STl959. Alternatively, peripheral blood mononuclear cells or Jurkat cells were activated with phorbol 12-myristate 13-acetate (PMA) (80 nM) and ionomycin (1 /lM) for 24 h. 3H-thymidine (0.5 /lCi/well) (PerkinElmer, Milan, Italy) was added during the last 8 h of stimulation before the cells were harvested and the uptake ofradioactivity quantified. Determination of cell death and apoptosis in peripheral blood mononuclear cells and Jurkat cells was done 6.5 h after stimulation by analyzing the cells for cell surface expression of Annexin V and propidium iodide staining by fluorescence-activated cell sorting (FACSCalibur and CellQuest software, Becton Dickinson, San Jose, CA). To measure intracellular IFN-y and IL-4 production, peripheral blood mononuclear cells (5xl0 6 cells/mL) were stimulated with 80 nM PMA and 1 J.!M ionomycin for 24 h. ST1959 was added at the start of stimulation and maintained throughout the experiment.
Nuclear extracts and measurement oftranscription factor activation
Human peripheral blood mononuclear cells or Jurkat cells (8x I0 6 cells/condition) were preincubated for 15 min with 30 /lM STI959 before stimulation with 80 nM PMA and 1 u.M ionomycin. After various time intervals, nuclear extracts were prepared according to recommendations by the manufacturer of the Nuclear Extract Kit (Active Motif Inc., Carlsbad, CA). Protein concentrations of the extracts were determined using the Bradford/Biorad method (BioRad Laboratories, Hercules, CA). The binding capacity of the transcription factors assayed in the nuclear or cytoplasmic extracts (4-10 mg/well) was determined using the specific Active Motif's TransAM Kits (Active Motif Inc., Carlsbad, CA).
Western blots
Peripheral blood mononuclear cells were treated with 
RNA protection assay
Peripheral blood mononuclear cells at 5x 105 cells/mL were incubated with 30 /lM STl959 or 50 nM cyclosporin A in 6-well plates for 30 min. After incubation, concanavalin A was added to a final concentration of 5 ug/ml., Cells were harvested 18 h later and RNA extracted using RNeasy Mini Kit (Qiagen S.p.A., Milan, Italy). Isolated RNA samples were then sent to PharMingen (BD PharMingen, San Diego, CA) for multi probe RNAse protection assay to assess the effects of STl959 on expression of a cytokine panel. The expression levels of individual cytokines were quantitated using a phosphoimager and normalized to the L32 mRNA expression.
Immunofluorescence
Cells to be analyzed by immunocytochemistry were stimulated with 80 nM PMA and I /lM ionornycin. Cells were incubated for 30 min with 30 u.M STl959 prior to stimulation. Nuclear export was inhibited by incubation with 100 nM leptomycin B (Calbiochem, San Diego, CA). Cells were centrifuged onto poly-L-Iysine-coated coverslips immediately after the indicated stimulation times and fixed at -20°C for 10 min in absolute methanol. After a permeabilization step with 0.1% Triton-XIOO in PBS for 5 min, cells were washed and non-specific binding sites were blocked by incubation with PBS containing I% fish skin gelatin. Incubation with anti-NFATI monoclonal antibody (BD Transduction Laboratories, San Diego, CA) was conducted for 2 h at room temperature followed by Alexa Fluor 568-conjugated goat antimouse immunoglobulin G (Invitrogen Co., Molecular Probes, Carlsbad, CA). After staining, the slides were washed repeatedly in phosphate buffered saline (PBS) and then mounted with 4' ,6-Diamidino-2-Phenylindole IVectashield mounting media (Vector Laboratories, Ltd, Peterborough, UK). All analyses and photography were performed on Eclipse 80i fluorescence microscope (Nikon Instruments S.p.A, Calenzano, Italy) equipped with a digital camera (DxH l200F-Nikon), connected to a Pentium V computer.
RESULTS
Protective effect of ST1959 on trinitrobenzene sulfonate-induced colitis
In initial studies, we determined the effect of STl959 administration on prevention of trinitrobenzene sulfonate-induced colitis in mice. We found that STl959 treatment of mice administered TNBS led to a reduction of colitis lesions, thus confirming previous results obtained in rats (4) . The ameliorating effects of STl959 on SJLlJ mice given ethanolic trinitrobenzene sulfonate via rectum were reflected in the macroscopic appearance of mouse colons. The animals treated subcutaneously with 0.5 mg/kg STl959 (on days 0, 2 and 4, after induction of colitis) showed less macroscopic ulceration of the colon (6% damaged colon area, ID) showed colons as healthy as those of normal non-treated animals (Fig. IC) . To ascertain whether the protective effect could be ascribed to a decreased local immunological response, we enriched lamina propria mononuclear cells from colon specimens and reactivated the cells in vitro with anti-CD3 and anti-CD28 monoclonal antibodies. The results showed that lamina propria mononuclear cells isolated from colitic animals treated with STl959 produced less IFN-y (Fig. IE) and IL-2 ( sulfonate. The amount of IFN-y and IL-2 was below the detection limit (100 pg/mL) of the ELISA assays when the cells were not re-stimulated in vitro. Next, we investigated whether the observed decrement of IFN-y and IL-2 production might be consequent to increased T helper-2 cytokines, such as IL-IO . Howe ver, we could not detect any increase in IL-I 0 production by lamina propria mononuclear cells after in vitro re-stimulation (data not shown).
Thus , these data suggest that ST 1959 could exert its activity by provoking blockage of IFN-y and IL-2 production and/or decreased proliferation of IFN-yand IL-2-producing cells.
ST1959 inhibits human T cell proliferation
To directly address the question of whether ST 1959 inhibits T cell proliferation, we first evaluated the effect of STl959 on the proliferation of human peripheral blood mononuclear cells stimulated with immobilized anti-CD3 and solub le anti-CD28 monoclonal antibodies. We found that STl959 inhibited proliferation in a concentrationdependent manner (Fig. 2A) . Moreover, this inhibition was not due to increased cell death , as determined by AnnexinV staining of cell membrane using fluore scence-activated cell sorting analysis (Fig . 28) . STl959 also inhibited proliferation of peripheral blood mononuclear cells (not shown) and Jurkat cells stimulated with 1 11M ionomycin and 80 nM PMA (Fig. 2C) , which mimics the activation of T cells through the C03 and C028 receptors, respectively. The EC so for Jurkat cells was calculated as 13.5±3.6 11M using ALLFIT software (14) . Inhibition by STl959 of PMA-and ionomycin-induced proliferation thus indicates that the inhibition is downstream of increased Ca2+ levels in the T-cell receptor signaling pathway and not simply due to toxicity, as shown by the lack of apoptosis at STl959 concentrations effective on cell proliferation (Fig. 20) . Moreover, this inhibition could not be rescued by IL-2 ( Fig. 2A) , thereby indicating that the effect of STl959 is not merely caused by decreased IL-2 production or inhibition of IL-2 receptor signaling.
ST1959 inhibits human T cell cytokine production
To ascertain whether decreased IFN-y levels were secondary to ST1959-induced reduction of the expansion of IFN-y-producing clones or if STl959 
. STl959 inhibits IFN-y production by human peripheral blood mononuclear cells. Peripheral blood mononuclear cells were seeded in 6-well plates (l.5x10 6 cells/well), treated for 30 min w/wo 30 pM STJ959, and then stimulated with 80 nM PMA and 1 p.M ionomycin. Intracellular staining after 24-h stimulation shows 27.7 and 3.1% of the cells positive for IFN-y (A) and IL-4 (B), respectively. The percentage of IFN-y-and IL-4-producing cells are 9% and 1A%, respectively, when peripheral blood mononuclear cells are stimulated in the presence of30 p.MSTJ959. The amount ofIFN-y produced by the IFN-y+ cells is also lower when peripheral blood mononuclear cells are activated in the presence of STJ959 (mean fluorescence intensity = 641) compared to cells activated in its absence (mean fluorescence intensity = 2677). Panel C shows fluorescence-activated cell sorting dot blot ofactivated peripheral blood mononuclear cells stained with IGG-APC and IGG-PE isotype control antibodies. The experiment represents one oftwo experiments performed.
also affected cytokine production at protein level, we performed an intracellular cytokine staining and fluorescence-activated cell sorting analysis of human peripheral blood mononuclear cells stimulated in vitro with 80 nM PMA and 1 11M ionomycin, with or without 30 11M STl959. After stimulation for 24 h, we found that the percentage of IFN-y and IL-4 positive cells diminished from 27.7 and 3.1% (Fig.  3A) to 9.0 and 1.4% (Fig. 3B) , respectively, when peripheral blood mononuclear cells were stimulated in the presence of STl959. In addition to these findings, the amount of intracellular IFN-y decreased from a mean fluorescence intensity value of 2677 to 641, thus showing that STl959 not only inhibits activation-dependent proliferation but also IFN-y synthesis. It was not possible to evaluate the effect of STl959 on IL-4 production due to the very low expression level in this experimental setting.
Inhibition of multiple cytokine mRNA expression by ST1959
Next, we determined whether STl959 inhibited a broader spectrum of cytokine gene expression in peripheral blood mononuclear cells activated by concanavalin A in the presence of STl959 or cyclosporin A, which were used as reference drugs. To this end, mRNA levels of a panel of cytokines were assessed using a multiprobe RNase protection 
. STl959 inhibits NFAT2 activation in human peripheral blood mononuclear cells and Jurkat cells. Peripheral blood mononuclear cells (I x lt)' cells/extract) or Jurkat cells (Ixl O' cells/extract) were cultured with (closed squares) or without (closed diamonds) 30 JIM STl959 for 30 min before stimulation with 80 nM PMA and 1 JIM ionomycinfor the times indicated in the figures. Nuclear proteins were extracted and 10 JIgassayedfor binding activity to immobilized oligonucleotides representative of appropriate gene response elements. To control for the binding specificity of the transcription factors to the immobilized oligonucleotides, nuclear extracts from cells activated in the absence ofSTl959 were mixed with the same oligonucleotides as coated in the wells (open triangles). Results are mean ± SEM of one of three representative experiments. STl959 inhibits the activity ofNFAT2 in peripheral blood mononuclear cells (A) and Jurkat cells (B) at all investigated time points. The DNA binding activity ofNF-KB (p50), AP-I (c-Jun) and CREB (C, D and E, respectively) in peripheral blood mononuclear cells was not affected by STl959. The experiments shown are representative ofthree (A, B, C) and two (D) experiments performed.
assay by selecting probes for IFN-y, IL-4, IL-9, IL-lO, IL-13 and IL-15. Table I shows that the inhibitory effect of STl959 was not restricted to IFN-y transcripts since IL-4, IL-I0 and IL-13 were also inhibited, while a mild or no effect was observed on IL-9 and IL-I5 expressions, respectively. ST 1959 and cyclosporin A affected both T-helper-I and T-helper-2 cytokine transcripts, although the relative inhibition ofIL-I 0 versus IFN-y transcripts differed between the two drugs. Inhibition of IL-I 0 was comparable between the two drugs whereas cyclosporin A was more potent in inhibiting IFN-y transcript expression. 
Effect ofST1959 on phosphorylation ofNFAT
To examine whether STl959, like cyclosporin A, inhibits NFAT dephosphorylation, thereby leading to inhibition ofNFAT nuclear import, we evaluated the effect of STl959 on NFATl phosphorylation in peripheral blood mononuclear cells pre-treated with 30 flM STl959 and stimulated with 80 nM PMA and 1 u.M ionomycin by performing Western blotting of whole celllysates using NFATl-specific antibodies. The phosphorylated and non-phosphorylated forms can be distinguished by their different mobility in sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). NFATl showed faster mobility in the gel from the sample activated for 1 h (Fig. 5, lane 2) compared to the sample of non-activated cells (Fig. 5, lane 1) . As expected, cyclosporin A inhibited the dephosporylation of NFATl (Fig. 5, lane 4) while STl959 did not (Fig.  5, lane 3) . This finding shows that STl959 affects NFATl by a mechanism different from that of cyclosporin A.
Effect of ST1959 on activation of different transcription factors
To investigate the molecular mechanisms underlying the inhibitory effect of STl959 on cytokine transcripts, we studied the effect of STl959 on activation of the NFAT, AP-l (c-Jun), NF-KB (P50), and cAMP response element-binding (CREB) transcription factors, important for,T cell activation and cytokine production, both in peripheral blood mononuclear cells and Jurkat cells stimulated with 80 nM PMA and 1 flM ionomycin. The DNA binding capacity of the transcription factors under investigation was determined using specific ELISA kits.
In peripheral blood mononuclear cells treated with 30 u.M STl959 for 0.5 h prior to stimulation, we found that STl959 inhibited NFAT2 activation (Fig. 4A ) but did not affect that of p50 (Fig. 4C) , CJun (Fig 4D) or CREB (Fig. 4E) . A similar inhibitory effect on NFAT2 was observed in Jurkat cells (Fig.  4B) , whereas the binding activity of p50, C-Jun or
Effect ofST1959 on NFAT nuclear trafficking
In an attempt to elucidate the mechanisms whereby STl959 exerts its effect, we investigated NFATI nuclear trafficking in Jurkat cells pretreated with STl959 and then stimulated with 80 nM PMA and 1 uM ionomycin, by carrying out immunofluorescence studies using NFATl-specific antibodies.
In non-activated cells, NFATl resided in the cytoplasm (Fig. 6A) , whereas in PMA/ionomycinactivated cells, NFATl localized to the nucleus (Fig.  6B) . In cells pre-treated with 30 flM STl959 before activation, more cells showed cytoplasmic NFATl localization (Fig. 6C) , as compared to cells activated in the absence of STl959 (Fig. 6B) . Calculating the percentage of cells with nuclear NFATl, we found that STl959 caused 70% inhibition of NFATl nuclear localization as early as 20 min after stimulation, which remained steady over the entire 2 h observation period (Fig. 60) inhibition on NFAT nuclear localization observed in Jurkat cells was also confirmed in human peripheral blood ' mononuclear cells (data not shown). These immunofluorescence resu lts agree with the ELISA data on DNA binding activity of NFAT reported in Fig. 4 . Inhibition of nuclear localization of NFATI by STI959 was confirmed by the examination of the expression of NFATI in nuclear and cytosolic fractions extracted from Jurkat cells (Fig. 6E) . The NF-KB subunit p50 was not inhibited in its nuclear localization after PMAJionomycin-activation (Fig.  6F) , which confirms that STl959 is not a general inhibitor of protein nucle ar-translocation.
In non-activated and activated cells, NFATl localizes to the cytoplasm (A) and the nucleus (B), respectively. In cells pretreated with STl959 and activated thereafter, NFATl localizes to the cytoplasm (C). Quantification of the inhibition of NFATl nuclear localization was carried out by counting the number of cells with predominantly nuclear NFATl (> 100 cells counted per condition and per experiment). STl959 inhibits activationinduced nuclear localization ofNFATl in peripheral blood mononuclear cells (D
To further ascertain whether ST l959 affects export rather than import from the nucleus, we pretreated Jurkat cells with leptomycin B (15) before treatment with STl959 and stimulation with PMA and ionomycin. We found that, in the presence of ST1959, NFATl localized to the cytoplasm (Fig.  7A) , and leptomycin B reversed the effect ofST1959, causing NFATI to localize to the nucleus (Fig. 7B) . The histogram (Fig. 7C) represents the average percentage of cells with cytoplasmic or nuclear immunofluorescence, corresponding to Fig. 7A -B. NFATI expression in nuclear extracts from Jurkat cells activated with PMA/ionomycin in the presence ofSTl959, revealed a nuclear increase ofNFATl in cells pre-treated with leptomycin B or ratjadone A (Fig. 70) . Since leptomycin Band ratjadone A are known chromosome region maintenance-dependent nuclear export inhibitors (16) , these results suggest a mechanism linking the effect of STl959 with increased nuclear egress ofNFAT.
DISCUSSION
In an earlier study in rats (4), it was shown that ST1959 is able to attenuate the acute colonic damage induced by ethanolic trinitrobenzene sulfonate and that the beneficial effect ofST1959 is associated with reduced colonic tissue levels of the proinflammatory cytokines IFN-y and TNF-a. This experimental model mimics human Crohn's disease (17) and is also responsive to drugs, like glucocorticosteroids, effectively utilized in the treatment of human inflammatory bowel disease (18) .
In the present study, we characterized the mechanism of action of STl959 in a mouse model of trinitrobenzene sulfonate-induced colitis. Lamina propria mononuclear cells, isolated from colitic mice treated with STl959 and subsequently stimulated in vitro with anti-CD3 and anti-CD28 monoclonal antibodies, showed a significantly reduced capacity to release two key pro inflammatory cytokines, namely, IFN-y and IL-2, in culture supernatants. These findings prompted us to investigate whether we could detect similar immunosuppressive effects on human T cells. We observed that ST1959 inhibited proliferation of peripheral blood mononuclear cells and Jurkat cells in a concentration-dependent manner, and that this effect was not related to increased apoptosis. STl959 inhibited anti-CD3-and anti-CD28-induced proliferation as well as PMAIionomycin-induced proliferation, suggesting that inhibition occurs downstream of increased Ca 2 + levels along the T-cell receptor signaling pathway. The EC50 value for the inhibition ofT cell proliferation and cytokine production by ST 1959 in vitro is probably higher than the blood levels reached after s.c. administration in our colitis model. In the in vivo experiments, however, ST 1959 was administered in sesame oil which acts as a depot for slow release of the drug product, thereby making it more potent (19) .
Since the promoter regions of the cytokines inhibited by STl959 contain several regulatory elements that can bind different transcription factors, including AP-l (Fos/Jun), NF-KB, and NFAT (20-25), we then studied whether ST1959 might affect activation of such factors. The results showed that STl959 selectively inhibited NFATl/2 activation, without impairing the activity of other inducible transcription factors, such as AP-l (Jun), NF-KB (p50), and CREB in peripheral blood mononuclear cells and Jurkat T cells stimulated by PMA/ionomycin.
At variance with other immunusuppressors, namely, cyclosporin and FK506, that act by inhibiting the calcium-dependent serine/threonine phosphatase calcineurin (9, 26) , ST1959 was unable to affect dephosphorylation of NFAT in peripheral blood mononuclear cells stimulated with PMA/ionomycin. Despite the lack of calcineurin inhibition, STl959 effectively reduced activation-induced nuclear localization ofNFATl. Taken together, these results demonstrate that STl959 inhibits T cell activation downstream of'Ca"-mediated influx, by a mechanism distinct from that of cyclosporin and FK506. These findings are reminiscent of the results obtained by others with pyrazole derivatives, a novel class of immunomodulators. In fact, pyrazole compounds cause NFAT to be maintained in the cytosol in a phosphorylated state, thereby blocking the nuclear import of NFAT and hence NFAT-dependent cytokine gene transcription by a mechanism other than direct inhibition of calcineurin phosphatase activity (27) (28) .
To further determine whether STl959 affects NFAT nuclear import or export, we carried out additional studies by using leptomycin Band ratjadone A, drugs that block the nuclear export of several proteins (29) . We observed that leptomycin Band ratjadoneAcaused an accumulation ofNFATl in the nucleus of PMA/ionomycin-activated Jurkat cells in the presence of ST1959, thus suggesting that ST1959 affects NFATl nuclear residency by promoting its export from the nucleus.
In conclusion, the present study demonstrates that ST1959 inhibits T cell activation by promoting nuclear export of the NFAT transcription factor. The decrease of NFAT in the nucleus can explain the macroscopic anti-inflammatory effects of ST1959 found in trinitrobenzene sulfonate-induced colitis in mice as well as in other inflammatory animal models (3) (4) (5) . Although additional studies are required to pinpoint the molecular target(s) involved in the inhibition of NFAT nuclear trafficking, we envision that ST1959, alone or in conjunction with other therapeutics, may be exploited clinically for the treatment of autoimmune/inflammatory disorders.
